Status:
COMPLETED
Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Chronic Iron Overload
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective, multicenter, non-interventional study. Findings are analyzed using epidemiological methods.
Detailed Description
This NIS shall document the therapy of chronic iron overload in a broad patient population with either of the approved iron chelators in Germany. The choice of patients and the therapy according to th...
Eligibility Criteria
Inclusion
- Male and female adult patients suffering from chronic iron overload
- who never received an iron chelator directly before starting an iron chelation therapy
- who received an iron chelation therapy for less than 6 month
- who interrupted an iron chelation therapy for longer than 6 months and will receive an iron chelation therapy again
- who signed the informed consent
Exclusion
- \-
Key Trial Info
Start Date :
September 15 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 29 2021
Estimated Enrollment :
489 Patients enrolled
Trial Details
Trial ID
NCT05440487
Start Date
September 15 2015
End Date
October 29 2021
Last Update
October 21 2022
Active Locations (102)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Heidenheim, Baden-Wurttemberg, Germany, 89518
2
Novartis Investigative Site
Mannheim, Baden-Wurttemberg, Germany, 68305
3
Novartis Investigative Site
Winnenden, Baden-Wurttemberg, Germany, 71364
4
Novartis Investigative Site
Aschaffenburg, Bavaria, Germany, 63739